Ocular Therapeutix (OCUL) Stifel 2026 Virtual Ophthalmology Forum summary

Regulatory alignment and trial design

• Full alignment with FDA guidelines issued in February 2023, emphasizing proper masking and relevant endpoints for retinal drug trials.

• Achieved Special Protocol Assessment (SPA) status, indicating the highest level of FDA agreement on trial design.

• SOL-1 trial met all four FDA evidentiary standards, including masking, powering, p-value (<0.0006), and safety population size.

• Ongoing formal discussions with the FDA support a path to single trial approval based on SOL-1.

• SOL-R continues for additional safety data and commercial leverage, but approval is expected to be filed on SOL-1 alone.

Clinical results and physician adoption

• SOL-1 demonstrated unprecedented disease control (OCT stability within 30 microns at month nine) and durability (2/3 rescue-free at month 12 with a single injection).

• Safety profile is described as completely clean and acceptable.

• Physicians are expected to adopt the drug immediately due to workflow compatibility and no added overhead.

• Anticipated use includes both fixed six-month dosing and treat-and-extend strategies, with flexibility left to physician preference.

• Drug is expected to perform better in real-world settings than in the clinical trial due to broader patient selection.

Competitive landscape and commercial strategy

• Emphasis on being first and best in class, with a superiority label and flexible dosing (every 6–12 months) targeted.

• SOL-R provides head-to-head data against EYLEA HD for commercial positioning and supports ex-US regulatory submissions.

• Physicians are encouraged to evaluate whether other companies have formal post-February 2023 FDA alignment.

• The control arm's strong performance in SOL-1 is considered academically interesting but not clinically relevant.